<DOC>
	<DOC>NCT02632474</DOC>
	<brief_summary>The purpose of this study is to determine efficacy of the combination of low dose of Tenofovir, Efavirenz and Lamivudine in treating HIV-infection.</brief_summary>
	<brief_title>ART Drug Dosage Adjustment in HIV-infected Population</brief_title>
	<detailed_description>The feedback system control (FSC) technique has been developed to rapidly identify optimal combinations for therapeutic purposes. Low dose of TDF+3TC+EFV combination has been test in vitro study by FSC which showed high efficacy and now the investigators apply it to human to further optimize the ART combination.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>HIV antibody positive HIV RNA below 10*E5 copies/ml CD4 T cell count above 200 cells/ml Provision of written informed consent HIV genotyping resistant to investigating drug Pregnant, breastfeeding, or lactating Any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with treatment, assessment, compliance with the protocol, or subject safety. This would include any active clinically significant renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease) illness, or malignancy Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol Laboratory blood values: Haemoglobin &lt;7.0 grams/decilitre (g/dL) Neutrophil count &lt;500/mm3 Platelet count &lt;50,000/mm3 Aspartate aminotransferase or Alanine transaminase &gt;5 times Upper Limit of Normal (ULN) Subjects with an estimated creatinine clearance of &lt;50 mL/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Tenofovir</keyword>
	<keyword>Efavirenz</keyword>
</DOC>